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Abstract 
PURPOSE: The objectives were to determine the effects of time-of-day consumption and 
training status on the benefits of caffeine supplementation for cycling performance and 
peak muscle strength. METHODS: Twenty untrained and trained subjects completed four 
trials consisting of isokinetic peak torque testing and 3-km time trials (TT). Subjects 
ingested either 6 mg/kg of caffeine or a placebo one hour prior to each trial. Treatments 
were: morning + placebo, morning + caffeine, evening + placebo, evening + caffeine. 
Magnitude based inferences were used to evaluate treatment differences. RESULTS: 
Caffeine (‘very likely’ and ‘likely’) improved 3-km TT performance in the morning and 
evening. 3-km TT performance was ‘likely’ improved more in the morning than evening 
for total subject pool and trained subjects. Untrained subjects ‘likely’ benefited more 
during the 3-km TT from supplementation than trained in both the morning and evening. 
Caffeine supplementation was ‘likely’ trivial and ‘unclear’ for the majority of peak muscle 
strength conditions. CONCLUSIONS: Caffeine supplementation improved 3-km TT 
performance in the morning for trained and untrained, with lesser benefits in the evening, 
while untrained benefited more than trained. Peak muscle strength was largely unaffected 
by caffeine supplementation, regardless of time-of-day consumption or training status.
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Chapter One 
Introduction 
 The ease and accessibility of caffeine is undeniable, and its use within sport is 
pervasive; among a sample of 20,686 urine samples, 33% of athletes testing positive for 
urinary caffeine levels above 5 µg/mL, approximate to the amount of caffeine in 3 cups of 
coffee (7). Caffeine is believed to exert its ergogenic effect through three possible 
mechanisms: 1) central nervous system (CNS) adenosine antagonism, 2) increased calcium 
release from the sarcoplasmic reticulum (within skeletal muscle), and 3) alteration of 
sodium-potassium ion pump activity; and these mechanisms may not be mutually 
exclusive. Caffeine and its metabolites are potent adenosine receptor antagonists (43, 56) 
due to similarity in molecular structure to adenosine (20, 59). This antagonism may 
enhance motor unit recruitment, as caffeine has been observed to increase maximum 
voluntary contraction (MVC) and recruitment above placebo levels (29, 54, 63). In vitro 
observation of caffeine on peripheral tissues showed increased calcium release from the 
sarcoplasmic reticulum, thought to have been produced by adenosine antagonism at the 
level of ryanodine receptors (RyR) (59). This antagonism allows for increased calcium 
release from the sarcoplasmic reticulum, allowing for greater levels of excitation 
contraction coupling to occur (36, 67). Finally, there is evidence of caffeine altering 
sodium-potassium pump dynamics, resulting in decreased plasma potassium 
concentrations (35). Better maintenance of electrochemical gradients extends the ability to 
deliver continuous action potentials. However, physiological doses do not appear to alter 
plasma potassium concentration (21). Inconsistent mechanistic findings may be due to 
discrepancies in dosages for research, with physiological dosing between 2-9mg/kg body 
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weight with a common dose of 6mg/kg body weight (3, 6, 8, 10, 12, 13, 15, 19, 63, 64), 
and supra-physiological dosages above toxic levels in humans for mechanistic actions (20, 
35, 59, 67). It is entirely possible all of these factors contribute to the ergogenic effect of 
caffeine and adenosine antagonism mediates all of these mechanisms (35, 43, 59). On 
balance, the current literature points to adenosine antagonisms working both centrally and 
peripherally. 
Regardless of the mechanism of action, the ergogenic properties of caffeine have 
been extensively studied during aerobic endurance performance, with enhancement 
observed during both long-duration (≥60 minutes) (12, 19, 25, 33, 57, 68), and short-
duration aerobic performance (2-60 minutes) (8, 19, 27, 45, 64). In 1979, Ivy et al. reported 
that 250mg of caffeine increased work output and oxygen consumption during two hours 
of isokinetic cycle ergometry (25). Since then, caffeine has been associated with improved 
work output (33), time to fatigue (19), and cycling time trial (TT) performance (12, 33, 
68). In a brief review of the literature, Graham found overwhelming support for the 
ergogenic properties of caffeine in long-duration performance, only noting three instances 
where no effect occurred (20). Research investigating caffeine supplementation prior to 
short-duration aerobic performance is less established than long-duration aerobic 
performance, although studies report faster race performance with caffeine (8, 45, 64). Our 
laboratory recently observed that caffeine enhanced 3km cycling TT performance by 1.1% 
(45). Additionally, improvements in time to fatigue at a given work rate have been 
observed with up to a 10 minute increase in exercise time at 85% VO2max (19, 27). 
Relative to caffeine and endurance performance, the effect on speed and power 
during anaerobic performance (≤2 minutes) is less clear (4). Caffeine can improve 
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swimming velocities and times during 100m swimming sprints in trained but not untrained 
individuals (10).  Similar improvements have been noted in mean power (13, 65), peak 
power (65), and TT performance (65). Importantly, the benefits of caffeine for anaerobic 
performance have not been universal. One study reported no change in peak power, total 
work, or the rate of power decay (66). Additionally, while Woolf et al. observed increased 
peak power in 78% of the subjects during administration of the Wingate test (69), other 
studies and meta-analyses found no effect (6, 15, 20, 21), with one even observing a 
detrimental effect (21) on Wingate performance. 
 The effect of caffeine on muscular strength, muscular power, MVC, and muscular 
endurance is equivocal, with more studies showing an effect (6, 15, 18, 41, 60, 69) than no 
effect (2, 3, 69). A recent meta-analysis performance on 27 muscular strength and 23 
muscular endurance studies yielded effect sizes of 4% and 14% gains in performance, 
respectively (63). However, there are inconsistencies in who benefits from caffeine 
supplementation, with some individuals responding more than others. This may be due to 
factors which have yet to be investigated in-depth, such as training status (2, 4, 20, 28, 33, 
60) and genetics (3, 4, 60).  
 Many environmental factors – such as diet, smoking, obesity, exercise, and 
menstrual related factors – have been linked to altered caffeine pharmacokinetics. 
Environmental factors inhibiting the activity of the enzyme responsible for caffeine 
metabolism, cytochrome P450 1A2  (CYP1A2), include: diet (16, 48, 49), menstrual 
related factors (oral contraceptives, luteal phase, post-menopausal estrogen replacement) 
(1, 17, 50) and obesity (1, 31); whereas factors inducing CYP1A2 activity include: diet (1, 
34, 49, 55) and smoking (1, 9, 16, 17, 42, 52, 53). Regarding exercise, chronic (61), but 
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not acute (31, 38) exercise appears to increase CYP1A2 activity and the pharmacokinetics 
of caffeine. When compared to resting metabolism, acute endurance exercise of 90 minutes 
failed to alter caffeine pharmacokinetics in lean or obese individuals (31, 38). Conversely, 
CYP1A2 activity increased after 30 days of endurance training (61). Separately from 
CYP1A2 activity, chronic endurance training causes increased adenosine receptor density 
(39). Training-induced physiological changes associated with caffeine metabolism and 
physiological interactions prove promising for differences in who benefits from caffeine.  
As mentioned above, training status may also mediate the magnitude of the 
ergogenic effect of caffeine. A meta-analysis indicated that untrained subjects may benefit 
more than trained subjects (63). However, virtually all of the insight on this topic has been 
derived from comparing separate studies conducted with trained and untrained subjects. 
To our knowledge, only three studies have included both trained and untrained in parallel 
design to distinguish the effect of training status. Collomp et al. evaluated the influence of 
training status on caffeine consumption during 100 m swim performance and observed 
trained, but not untrained swimmers benefited from consumption (10). Conversely, two 
studies observing cycling time-to-fatigue and peak strength noted no significant differences 
between trained and untrained (7, 51). However, it should be noted neither study observed 
that caffeine elicited a significant effect on performance. The influence of the ergogenic 
properties of caffeine as they pertain to training status on muscular strength and power or 
short-duration aerobic performance is still unclear. 
Time-of-day variations have been identified in both CYP1A2 activity and physical 
performance. Increases in CYP1A2 activity in the morning when compared to the 
afternoon occur in both South Asian and Caucasian individuals (47). Similarly, CYP1A2 
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activity appears to be elevated during sleeping hours and directly after waking, when 
compared to the rest of day (30). Few studies have evaluated the effect of time-of-day 
caffeine consumption on performance. To date, one study from this lab on aerobic 
performance with coincidental design (45), and two deliberately designed time-of-day 
studies observing muscular strength and power (40, 41), witnessed time-of-day influencing 
the ergogenic effect of caffeine, with caffeine raising performance levels in the morning to 
match those observed in the afternoon or evening. However, no deliberately designed study 
has observed time-of-day influence ergogenic effect in aerobic performance. 
The ease and accessibility of caffeine is undeniable, and its use within sport is 
pervasive. However, a number of major candidate factors involved in caffeine and 
performance have yet to be resolved. Caffeine metabolism is regulated by many factors; 
some controllable such as time-of-day (30, 47) and diet (16, 34, 48, 49, 55); while others 
are not controllable, such as aspects related to menstruation (1, 17, 38, 50, 53). 
Additionally, training status appears to impact whether or not an individual benefits from 
supplementation (8, 15, 19, 27, 40, 41, 64). Therefore, it is important to study each aspect 
and its role in the ergogenic properties of caffeine for physical performance. 
 
Purpose 
The purpose of the current study is to detail the extent that time-of-day consumption 
and training status influence caffeine’s effect on 3km time trial performance and peak 
isokinetic leg strength. 
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Aims and Hypotheses 
Aim 1: To determine if time-of-day consumption mediates the effects of caffeine 
supplementation on peak isokinetic leg torque. 
Hypothesis 1: Caffeine will elicit larger improvements in peak torque among morning than 
evening consumption.  
Aim 2: To determine if time-of-day consumption mediates the effects of caffeine 
supplementation on a 3km cycling time trial. 
Hypothesis 2: Caffeine will elicit larger improvements in 3km cycling time trial among 
morning than evening consumption. 
Aim 3: To determine if training status mediates the effects of caffeine supplementation on 
peak isokinetic leg torque. 
Hypothesis 3: Caffeine will elicit larger improvements in peak torque among untrained 
than trained individuals. 
Aim 4: To determine if training status mediates the effects of caffeine supplementation on 
a 3km cycling time trial. 
Hypothesis 4: Caffeine will elicit larger improvements in 3km cycling time among 
untrained than trained individuals.  
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Significance 
Major candidate factors affecting who benefits from caffeine supplementation have 
yet to be resolved, warranting investigation into the factors influencing caffeine’s 
ergogenic properties. Time-of-day consumption appears to affect the value of caffeine, but 
the literature investigating this interaction is too young to make any definitive verdict on 
the interaction. Further, untrained individuals appear to experience greater benefits from 
caffeine supplementation, yet only a few study have observed trained versus untrained in 
the same design. Relatively few studies have randomized, double-blind, crossover, placebo 
controlled designs investigating the effect of time-of-day consumption and training status 
on the ergogenic properties of caffeine, and none have investigated both of these 
parameters and the cross-treatment interaction on caffeine supplementation in both short-
duration aerobic and muscular strength performance that may occur in a single study. The 
findings from the current study have the potential to determine which of the major 
candidate factors (time-of-day consumption and training status) affect whom benefits from 
caffeine supplementation regarding short-duration aerobic and muscular performance.  
8 
 
 
Chapter Two 
Methodology 
Subjects 
 Sixty healthy male subjects – thirty trained cyclists and thirty novice cyclists – from 
James Madison University will participate in this study. All subjects are required to have 
performed, at minimum, either “occasional” cycling (one day per month) in their weekly 
exercise routine for the novice cyclists, or “consistent” cycling (four days per week) in 
their weekly exercise routine over the previous three months for the trained cyclists.  
Females are excluded from the current study because of fluctuating caffeine 
pharmacokinetics. Specifically caffeine clearance is reduced during the luteal phase of 
menstrual cycle as well as a result of certain types of oral contraception usage (1, 17, 50). 
Subjects will be informed of the experimental procedures and risks prior to giving written 
consent. The study was approved by the James Madison University Institutional Review 
Board.  
 
Fitness Testing 
 Following height and body weight measurements, subjects perform an incremental 
exercise test to exhaustion on a bicycle ergometer (Velotron, Racermate, Inc., Seattle, WA, 
USA) to determine maximum oxygen consumption (VO2max). The workload starts at 100 
W for untrained and 150 W for trained, and increases every minute in 25 W increments 
until volitional fatigue, or inability of the subject to maintain a cadence of 50 RPM or 
higher for more than 10 seconds. Metabolic measurements is assessed via Moxus Modular 
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Metabolic System (AEI Technologies, Pittsburgh, PA, USA) throughout the test and 
VO2max will be determined by the highest 30-s mean oxygen uptake value. 
 
Supplementation 
 A randomly counterbalanced, double blind, placebo controlled design will be 
implemented to compare the effects of the four different treatment conditions. During the 
experimental trials subjects are given 6mg/kg body weight in capsule form containing 
either anhydrous caffeine or all-purpose flour (placebo), which will be ingested 1 hour prior 
to each treatment trial. Additionally, subjects will perform four trials: two morning (6:00am 
to 10:00am), and two evening (4:00pm to 8:00pm). Morning and evening trials will be 
repeated at identical times, with an eight-hour minimum separation between designated 
morning and evening times. The four treatment conditions are: 1. Morning + placebo 
capsule (AMPLA) 2. Morning + caffeine capsule (AMCAF) 3. Evening + placebo capsule 
(PMPLA) 4. Evening + caffeine capsule (PMCAF). 
 
Performance Trials 
 Each subject performs six exercise trials (two familiarization trials followed by four 
experimental trials) on both an isokinetic dynamometer (Biodex Multi-Joint System - PRO, 
Biodex Medical Systems, Inc., Shirley, NY, USA), and the aforementioned cycle 
ergometer, with 3-14 days between each trial. The subjects perform a 5-minute treadmill 
warm-up at 3.5 mph. Following warm-up, subjects complete six sets composed of two 
warm-up repetitions on the isokinetic dynamometer, followed by two maximal exertion 
isokinetic peak torque measurements at 30, 120, and 240°/sec. One repetition consists of 
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knee extension immediately followed by knee flexion. Once all exertions are completed in 
a given set, 60-seconds of rest is given before proceeding to the next set. Once two sets are 
completed at a given velocity, the subject moves to the next velocity for two sets, moving 
from slowest to fastest velocity in set progression. After the isokinetic peak torque 
measurements, subjects perform a 3km time trial. The familiarization trials are identical to 
the experimental trials, with the exception of treatment. Subjects are instructed to treat each 
trial as a competition. Subjects will not receive verbal feedback or encouragement from the 
investigators and no visual feedback from the time trial will be provided, with the exception 
of elapsed distance for the 3km time trial. 
 A mean of the peak torques from both maximal attempts during the isokinetic 
testing during both knee flexion and knee extension will be analyzed to determine if 
differences are present between treatments. Similarly, time trial time and mean power 
output will be analyzed to determine if any differences are present between treatments.  
 After the completion of every trial, subjects are given a questionnaire asking which 
supplementation protocol (caffeine or placebo) subjects believed was administered during 
each trial, as well as asked to give a confidence rating for each trial’s prediction.  
 
Dietary and Exercise Control 
 Subjects are provided with instructions for recording food intake so subsequent 
dietary intake could be replicated. All subjects record food intake for 24 hours prior to all 
experimental trials and are instructed to replicate food intake for each experimental trial. 
Subjects are instructed to abstain from any alcohol (24 hrs), caffeine (12 hrs), and food 
intake (4 hrs; post-absorptive state) prior to each experimental trial. All subjects record 
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daily physical activity for 48 hours prior to experimental trials. Subjects will be instructed 
to maintain consistent exercise habits between trials and to abstain from any heavy and/or 
unaccustomed exercise 48 hours prior to each experimental trial. Dietary and exercise 
records will be obtained prior to each experimental trial. 
 
Statistical Analysis 
All data will be log transformed to diminish the effects of nonuniformity. 
Magnitude-based inferences about the data will be derived using methods described by 
Hopkins and colleagues (22). A previously established ‘smallest worthwhile change’ in 
performance is used as the threshold value for a substantial treatment effect (separate 
treatment conditions vs. placebo) (24). The smallest worthwhile change in performance is 
defined as 0.3 × the within-subject variability of select groups of elite cyclists across 
repeated time trials (CV = 1.3% for time and estimated 3.25% for power), which translates 
to a difference in mean power output of 1% or 2.4 watts and 0.4% or 1.2-seconds in the 
current project (46). For the isokinetic data, 0.2 × SD of the AMPLA trial will be used to 
determine smallest worthwhile change (24).  
A published spreadsheet (23) will then be used to determine the likelihood of the 
true treatment effect (of the population) reaching the substantial change threshold (0.3 x 
CV); these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-
25% = unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = 
almost certain. If the percent chance of the effect reaching the substantial change threshold 
is <25% and the effect will be clear, it will be classified as a ‘trivial’ effect. If 90% 
confidence intervals include values exceeding the substantial change threshold for both a 
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positive and negative effect, effects will be classified as unclear (>5% chance of reaching 
the substantial threshold for both a positive and negative effect).   
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Chapter Three 
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ABSTRACT 
 
PURPOSE: The objectives were to determine the effects of time-of-day consumption and 
training status on the benefits of caffeine supplementation for cycling performance and 
peak muscle strength. METHODS: Twenty untrained and trained subjects completed four 
trials consisting of isokinetic peak torque testing and 3-km time trials (TT). Subjects 
ingested either 6 mg/kg of caffeine or a placebo one hour prior to each trial. Treatments 
were: morning + placebo, morning + caffeine, evening + placebo, evening + caffeine. 
Magnitude based inferences were used to evaluate treatment differences. RESULTS: 
Caffeine (‘very likely’ and ‘likely’) improved 3-km TT performance in the morning and 
evening. 3-km TT performance was ‘likely’ improved more in the morning than evening 
for total subject pool and trained subjects. Untrained subjects ‘likely’ benefited more 
during the 3-km TT from supplementation than trained in both the morning and evening. 
Caffeine supplementation was ‘likely’ trivial and ‘unclear’ for the majority of peak muscle 
strength conditions. CONCLUSIONS: Caffeine supplementation improved 3-km TT 
performance in the morning for trained and untrained, with lesser benefits in the evening, 
while untrained benefited more than trained. Peak muscle strength was largely unaffected 
by caffeine supplementation, regardless of time-of-day consumption or training status.  
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INTRODUCTION 
 The ease and accessibility of caffeine is undeniable, and its use within sport is 
pervasive; among a sample of 20,686 urine samples, 33% of athletes testing positive for 
urinary caffeine levels above 5 µg/mL, approximate to the amount of caffeine in 3 cups of 
coffee (7). The benefits of caffeine have consistently been shown to enhance performance 
longer in events lasting longer than 2 minutes (17, 21, 25, 32, 34), whereas data on shorter 
duration events and peak muscle strength are less conclusive. Specifically, caffeine intake 
can enhance anaerobic power and speed (6, 8, 33), yet repeated 30-second Wingate 
Anaerobic Test performance does not appear to be impacted by caffeine supplementation 
(4, 10, 13). Likewise, the influence of caffeine on muscular strength, power, endurance, 
and maximal voluntary contraction (MVC) is equivocal, with some (4, 10, 11, 23) but not 
all studies (1, 2) supporting an ergogenic effect of caffeine. Altogether, it is clear that 
caffeine has the capacity to improve physical performance. Importantly, there are a number 
of unresolved factors that may impact the magnitude of the effect of caffeine, including 
time of day and training status. 
 Time-of-day has recently been shown to influence the performance impact of 
caffeine supplementation. To date, only two studies have investigated the potential time-
of-day × caffeine interaction and both indicated that caffeine benefits may be heighted in 
the morning compared to the evening. Mora-Rodríguez et al. investigated caffeine’s effect 
on bench press, squat, and MVC, noting placebo trials in the morning were below the 
performance of all other trials for bench press. No differences were observed between the 
morning caffeine trials and either of the evening trials (caffeine or placebo) (23), indicating 
caffeine attenuated morning deficits in somatic performance. Additionally, our lab recently 
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studied caffeine supplementation on 3-km time trial performance, and added post-hoc 
grouping into ‘before 10am’ vs. ‘after 10am’ performance for parallel comparison (25). 
Caffeine ingestion improved ‘before 10am’ performance while the improvement of 
performance ‘after 10am’ with caffeine was unclear. Because only one crossover designed 
study assessed time-of-day caffeine consumption and muscular performance and our recent 
post-hoc analysis revealed caffeine may elicit greater improvements in the morning, the 
primary purpose of this study was to observe the effect of time-of-day on caffeine 
ergogenics. 
As mentioned above, training status may also mediate the magnitude of the 
ergogenic effect of caffeine. A meta-analysis indicated that untrained subjects may benefit 
more than trained subjects (31). However, virtually all of the insight on this topic has been 
derived from comparing separate studies conducted with trained and untrained subjects. 
To our knowledge, only three studies have included both trained and untrained in parallel 
design to distinguish the effect of training status. Collomp et al. evaluated the influence of 
training status on caffeine consumption during 100 m swim performance and observed 
trained, but not untrained swimmers benefited from consumption (6). Conversely, two 
studies observing cycling time-to-fatigue and peak strength noted no significant differences 
between trained and untrained (5, 27). However, it should be noted neither study observed 
that caffeine elicited a significant effect on performance. The influence of the ergogenic 
properties of caffeine as they pertain to training status on muscular strength and power or 
short-duration aerobic performance is still unclear. Therefore, the second purpose of this 
study was to observe the effect of training status on caffeine ergogenics. 
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METHODOLOGY 
Subjects 
 Twenty-two healthy male subjects (twelve trained and ten novice cyclists) from 
James Madison University and the surrounding area volunteered for the study. However, 
one trained and one novice cyclist withdrew for reason unrelated to the study, resulting in 
a sample of eleven trained and nine novice cyclists who completed the study. Descriptive 
data are shown in Table 1. Subjects were required to have performed, at minimum, either 
“occasional” cycling (one day per month) for the novice cyclists, or “consistent” cycling 
(four days per week) in their weekly exercise routine over the past three months for the 
trained cyclists. Cycling frequency and duration were self-reported. Trained and untrained 
cyclists were determined by the number of hours cycling per week for the 3km data, with 
comparison based off the top (trained) vs. bottom (untrained) tertiles. Subjects were asked 
about their resistance training habits and this information was used to permit post-hoc 
separation into binomial groups of resistance trained (10.1 ± 7.8 hrs/wk, range: 3.5-22.5 
hrs/wk) and untrained (0.6 ± 0.7 hrs/wk, range: 0-2 hrs/wk) for use as a covariate. Subjects 
were informed of the experimental procedures and risks prior to giving written consent. 
The study was approved by the James Madison University Institutional Review Board.  
 
Cardiovascular Fitness Testing 
 Following height and body weight measurements, subjects performed an 
incremental exercise test to exhaustion on a bicycle ergometer (Velotron, Racermate, Inc., 
Seattle, WA, USA) to determine maximum oxygen consumption (VO2max). The workload 
started at either 100 or 150 W for untrained and trained, respectively, and was increased 
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by 25 W every minute until volitional fatigue. Metabolic measurements were assessed 
using a Moxus Modular Metabolic System (AEI Technologies, Pittsburgh, PA, USA) 
throughout the test and VO2max was determined by the highest 30-second mean oxygen 
uptake. 
 
Experimental Design 
 A randomly counterbalanced, double blind, placebo controlled design was 
implemented to compare the effects of the four different treatment conditions. During the 
experimental trials subjects ingested a capsule one hour prior to exercise containing either 
6 mg/kg body weight anhydrous caffeine or all-purpose flour (placebo). Subjects 
performed four trials: two morning (6:00am to 10:00am), and two evening (4:00pm to 
8:00pm). Morning and evening trials were repeated at their respective identical time, with 
an eight-hour minimum separation between designated morning and evening times. The 
four treatment conditions were: 1. Morning + placebo capsule (AMPLA) 2. Morning + 
caffeine capsule (AMCAF) 3. Evening + placebo capsule (PMPLA) 4. Evening + caffeine 
capsule (PMCAF). 
 
Performance Trials 
 Each subject performed six exercise trials (two familiarization trials followed by 
four experimental trials) on both an isokinetic dynamometer (Biodex Multi-Joint System - 
PRO, Biodex Medical Systems, Inc., Shirley, NY, USA), and cycle ergometer, with 3-14 
days between each trial. The subjects performed a 5-minute treadmill warm-up at 3.5 mph. 
Following warm-up, subjects completed six sets composed of two warm-up repetitions on 
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the isokinetic dynamometer, followed by two maximal exertion isokinetic peak torque 
measurements at 30, 120, and 240 degrees/sec on their right leg. Each repetition consisted 
of knee extension immediately followed by knee flexion. Once all repetitions were 
completed in a given set, 60-seconds of rest was given before proceeding to the next set. 
After completing two sets at a given velocity, subjects performed the next velocity for two 
sets, progressing from slowest to fastest in velocity. A mean of the peak torques from both 
maximal attempts during the isokinetic testing during both knee flexion and knee extension 
were analyzed to determine if differences were present between treatments. After the 
isokinetic peak torque measurements, subjects performed a 3-km time trial on the cycle 
ergometer. The familiarization trials were identical to the experimental trials, with the 
exception of treatment. Subjects were instructed to treat each trial as a competition. 3-km 
time trial time and mean power output were analyzed to determine if any differences were 
present between treatments. Subjects did not receive verbal feedback or encouragement 
from the investigators during testing and no visual feedback from the time trial were 
provided, with the exception of elapsed.  
 After the completion of the all trials, subjects were given a questionnaire asking 
which supplementation protocol (caffeine or placebo) subjects believed was administered 
during each trial, as well as asked to give a confidence interval for each trial’s prediction.  
 
Dietary and Exercise Control 
 Subjects were provided with instructions for recording food intake so dietary intake 
could be replicated across trials. All subjects recorded food intake for 24 hours prior to all 
experimental trials and were instructed to replicate food intake for each experimental trial. 
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Subjects were also instructed to abstain from any alcohol (24 hrs), caffeine (12 hrs), and 
food intake (4 hrs; post-absorptive state) prior to each experimental trial. Daily physical 
activity was also recorded for 48 hours prior to experimental trials. Subjects were instructed 
to maintain consistent exercise habits between trials and to abstain from any heavy and/or 
unaccustomed exercise 48 hours prior to each experimental trial. Dietary and exercise 
records were collected prior to each experimental trial. 
 
Statistical Analysis 
All data were log transformed to diminish the effects of nonuniformity. Magnitude-
based inferences about the data were derived using methods described by Hopkins and 
colleagues (14). A previously established ‘smallest worthwhile change’ in performance 
was used as the threshold value for a substantial treatment effect (separate treatment 
conditions vs. placebo) (16). The smallest worthwhile change in performance was defined 
as 0.3 × the within-subject variability of select groups of elite cyclists across repeated time 
trials (CV = 1.3% for time and estimated 3.25% for power), which translated to a difference 
in mean power output of 1% or 2.4 watts and 0.4% or 1.2-seconds in the current project 
(26). For the isokinetic data, 0.2 × SD of the AMPLA trial was used to determine smallest 
worthwhile change (16).  
A published spreadsheet (15) was then used to determine the likelihood of the true 
treatment effect (of the population) reaching the substantial change threshold (0.3 x CV); 
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% = 
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost 
certain. If the percent chance of the effect reaching the substantial change threshold was 
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<25% and the effect was clear, it was classified as a ‘trivial’ effect. If 90% confidence 
intervals included values exceeding the substantial change threshold for both a positive and 
negative effect, effects were classified as unclear (>5% chance of reaching the substantial 
threshold for both a positive and negative effect).   
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RESULTS 
3-km Time Trial Performance 
All Subjects 
 In all subjects, AMCAF 3-km time and power output (3-km TT) was ‘very likely’ 
better than AMPLA, while PMCAF ‘likely’ improved performance vs. PMPLA (Figures. 1 and 
2). AMCAF ‘likely’ improved 3-km TT performance to a greater extent than PMCAF when 
compared to the respective placebo condition (PLA) (Table 2).  
 
Trained Subjects 
 For trained subjects, AMCAF performance was ‘likely’ improved vs. AMPLA, 
whereas caffeine’s effect was ‘unclear’ between PMPLA and PMCAF for 3-km TT. AM vs. 
PM comparison revealed that AMCAF ‘likely’ improved performance more than PMCAF 
when compared to PLA. 
 
Untrained Subjects 
 AMCAF and PMCAF ‘likely’ improved time trial performance vs. AMPLA and PMPLA, 
respectively, in untrained subjects. Time-of-day AM vs. PM comparison was ‘unclear’. 
 
Training Status 
 It was ‘unclear’ whether trained or untrained benefited more from caffeine in the 
AM condition, but untrained subjects ‘likely’ benefited more from caffeine 
supplementation than trained in the PM condition. 
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Peak Muscle Force 
All Subjects 
 For all peak muscle force data, see Table 2 and 3. Caffeine ‘possibly’ decreased 
torque 30 deg/sec flexion (30FLX) in the AM, 120 deg/sec flexion (120FLX), and 240 
deg/sec flexion (240FLX) conditions, whereas caffeine’s influence was ‘likely’ trivial in 
the AM for all other conditions. 30EXT performance was ‘possibly’ improved by caffeine 
in the PMCAF trial when compared to PMPLA, but all other conditions were ‘likely’ trivial 
regarding PM performance and caffeine. Caffeine ‘possibly’ increased PMCAF torque more 
than AMCAF torque in the 30EXT condition when compared to PLA. All other conditions 
from AM vs. PM comparison revealed trivial or ‘unclear’ findings. 
 
Trained Subjects 
 AMCAF performance was ‘unclear’ or ‘likely’ trivial for all conditions when 
compared to AMPLA for trained subjects. For PMCAF compared to PMPLA, trained subjects 
‘possibly’ improved with caffeine for 30EXT, ‘possibly’ were harmed by caffeine for 
240FLX, and the remaining conditions were ‘unclear’ or ‘likely’ trivial. All conditions 
were ‘unclear’ regarding AMCAF vs. PMCAF when compared to PLA. 
 
Untrained Subjects 
 Caffeine supplementation ‘possibly’ benefited in the AMCAF trial over the AMPLA 
trial for the 30EXT condition for untrained subjects. All other conditions for AMPLA vs. 
AMCAF, PMPLA vs. PMCAF, and AMCAF vs. PMCAF when compared to PLA were ‘unclear’ 
for caffeine ingestion in untrained subjects. 
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Training Status 
 All conditions were ‘unclear’ regarding caffeine and training status in both the AM 
and PM trials. 
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DISCUSSION 
 The purpose of the current study was to investigate how time-of-day and training 
status consumption influences the ergogenic effects of caffeine for both 3-km TT 
performance and peak muscle strength. We observed several key findings related to both 
time-of-day and training status. Specifically, caffeine increased 3-km TT performance in 
the AM more than in the PM (all subjects and trained subjects). Caffeine also improved 
cycling performance for the untrained in both the AM and PM, but benefit for trained was 
‘likely’ in the AM and ‘unclear’ in the PM. Caffeine intake also benefited 3-km 
performance more among untrained subjects, compared to their trained counterparts. Peak 
muscle force data was less conclusive, as almost all non-trivial and ‘unclear’ findings were 
with the total subject pool. Additionally, all data regarding peak strength – except for the 
total subjects during the 30EXT condition – showed no interaction between time-of-day 
and caffeine performance. 
 Consistent with our general hypothesis, caffeine enhanced 3-km TT performance 
among trained subjects in the morning but not the evening. This may be related to the 
slower time trial performances in the morning compared to the evening, in the absence of 
caffeine. Research has documented morning deficits in somatic control and performance 
in both trained and untrained subjects (3, 20, 24, 28). In support of our data, both Mora-
Rodríguez et al. and Pataky et al. observed caffeine supplementation in strength trained 
and recreationally trained cyclist, respectively. AM caffeine supplementation returned 
performance to the level of, but not beyond both PM trials with supplementation, indicating 
an attenuation these deficits (23, 25). Unlike the trained subjects, untrained subjects ‘likely’ 
rode faster with caffeine in both AM and PM, compared to PLA. While the time-of-day 
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interaction for the untrained group was ‘unclear’, subjects appeared to experience more of 
a caffeine benefit in the morning (5.5% ± 4.3) than in the evening (2.9% ± 2.6%). Slower 
AMPLA performances when compared to PMPLA may be culpable, but both AMCAF and 
PMCAF achieved the same finishing times. While attenuation of morning deficits may 
explain some of these findings, this cannot completely explain the increase in PMCAF from 
PMPLA. Though speculative, improved pacing patterns and time-to-fatigue in the untrained 
subjects may have resulted in improvements in PMCAF performance as caffeine has 
previously been found to increase time-to-fatigue (12). Untrained subject pacing patterns 
may not be as optimized as trained, leading to premature fatigue. Increased time-to-fatigue 
would allow for less influence of suboptimal pacing, leading to larger increases in AMCAF 
performance, as well as improvements in PMCAF performance.  
Our data indicate that untrained subjects respond more favorably to caffeine 
supplementation than trained subjects. Porterfield et al. did not observe any benefit from 
caffeine in either trained nor untrained. However, these investigators did report trends 
suggesting greater increases in cycling time-to-fatigue in untrained (10.2%) vs. trained 
(3.1%) (27), which partially supports our findings. Further, while Collomp et al. reported 
that trained but not untrained individuals benefited from caffeine supplementation (6), our 
data suggest that untrained subjects ‘likely’ benefited more from caffeine than trained for 
3-km TT performance with both morning and evening supplementation. However, our data 
does support previous meta-analysis data with untrained benefiting more from caffeine 
than trained (31). Furthermore, we did not observe any obvious effect of caffeine on peak 
muscle force nor an influence from training status as previously seen by Brooks et al. (5). 
Differences in the current findings and those of Collomp et al. may be due to exercise 
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mode. Collomp et al. examined swimmers, which has a large upper-body component to it, 
whereas the current study and the majority of previous literature used lower-body dominant 
exercise modes. We question the ability of untrained swimmers to translate increases in 
power output to faster swimming times, as swimming is a less trained, more technical 
biomechanical movement than running or cycling. 
 Overall, peak muscle strength is largely unaffected by caffeine except ‘possibly’ at 
slow speeds of contraction for knee extension. These data agree with some findings in the 
literature showing no benefit from caffeine in muscular performance (1, 2, 35), but are in 
opposition to the majority of studies which suggest an ergogenic benefit from caffeine 
supplementation (4, 10, 11, 23, 29, 35). Timmins et al. found caffeine elicited a smaller 
magnitude of effects in muscle groups with smaller mass (29), which may explain the 
trivial and ‘unclear’ results found as hamstring muscle mass is smaller than quadriceps 
mass (9). Moreover, a recent meta-analyses revealed that caffeine effects are more 
noticeable in knee extensor data (ES = 0.37) when compared to other muscle groups (ES 
= 0.06) (31). Further, as angular velocity increases, so do the number of ‘unclear’ and trivial 
analyses, indicating there may be a velocity interaction. As velocity increases, the 
recruitment of faster motor units (fast-twitch muscle) increases (30), indicating a greater 
percentage of the working muscle to be fast-twitch and less to be slow-twitch contribution 
(18). Jacobson et al. supports this idea as isokinetic data on elite athletes showed significant 
findings for caffeine consumption during knee extensor, and not knee flexor data, with 
increased performance at slower angular velocities (19). Lynge and Hellsten  found greater 
adenosine receptor density in slow-twitch muscle, which would suggest caffeine to benefit 
slow-twitch fibers as caffeine’s mechanism of action is adenosine antagonism (22). 
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Therefore, as velocity increases, it is possible that the fiber type that benefits from caffeine 
supplementation would represent a smaller percentage of recruited motor units, resulting 
in less of an effect. This would explain why greater results were noted in the 3-km data 
while peak strength data, with the exception of 30EXT, was largely unaffected. 
 One of the limitations of the current study is the relatively small sample size for 
parallel comparisons. Large numbers of ‘unclear’ semantic inferences may be caused by 
sensitivity of the data to individual differences and outliers (no subject data surpassed 3 
SD above the mean) due to the small sample size. Further studies should aim to increase 
sample size to allow for more definitive results regarding any training status differences, 
as there is a great deal still unknown. Despite these limitations, our data still supports 
caffeine attenuating AM deficits in trained, and more benefit in untrained when compared 
to trained. 
 The findings of this study support the idea that time-of-day and training status 
influences caffeine ergogenics. Our data supported previous data regarding both benefit 
from caffeine in AM performance for time-of-day, as well as a larger ergogenic effect in 
untrained compared to trained individuals. The research on both factors is still sparse, and 
more information is needed before personalized prescription for optimal performance 
outcomes can be made. Due to the equivocal results of the current study and literature on 
training status and caffeine, subsequent studies should observe larger sample sizes for 
training status. Additionally, research should inspect the possibility of a time-of-day × 
genetic interaction which has been proposed by previous studies and the current, as well 
as try to pinpoint the conditions in which caffeine is ergogenic for muscular performance. 
  
30 
 
 
Manuscript References 
1.  Astorino T a, Rohmann RL, Firth K. Effect of caffeine ingestion on one-repetition 
maximum muscular strength. Eur J Appl Physiol 2008;102(2):127–32. 
2.  Astorino TA, Martin BJ, Schachtsiek L, Wong K, Ng K. Minimal effect of acute 
caffeine ingestion on intense resistance training performance. J Strength Cond Res 
2011;25(6):1752–8. 
3.  Atkinson G, Todd C, Reilly T, Waterhouse J. Diurnal variation in cycling 
performance: influence of warm-up. J Sports Sci 2005;23(3):321–9. 
4.  Beck TW, Housh TJ, Schmidt RJ, et al. The acute effects of a caffeine-containing 
supplement on strength, muscular endurance, and anaerobic capabilities. J Strength 
Cond Res 2006;20(3):506–10. 
5.  Brooks JH, Wyld K, Chrismas BCR. Acute Effects of Caffeine on Strength 
Performance in Trained and Untrained Individuals. J Athl Enhanc 2015;(April) 
6.  Collomp K, Ahmaidi S, Chatard JC, Audran M, Préfaut C. Benefits of caffeine 
ingestion on sprint performance in trained and untrained swimmers. Eur J Appl 
Physiol Occup Physiol 1992;64(4):377–80. 
7.  Del Coso J, Muñoz G, Muñoz-Guerra J. Prevalence of caffeine use in elite athletes 
following its removal from the World Anti-Doping Agency list of banned 
substances. Appl Physiol Nutr Metab 2011;36(4):555–61. 
8.  Doherty M, Smith P, Hughes M, Davison R. Caffeine lowers perceptual response 
and increases power output during high-intensity cycling. J Sports Sci 
2004;22(7):637–43. 
9.  Evangelidis PE, Massey GJ, Pain MTG, Folland JP. Strength and size relationships 
of the quadriceps and hamstrings with special reference to reciprocal muscle 
balance. Eur J Appl Physiol 2016;116(3):593–600. 
10.  Forbes SC, Candow DG, Little JP, Magnus C, Chilibeck PD. Effect of Red Bull 
energy drink on repeated Wingate cycle performance and bench-press muscle 
endurance. Int J Sport Nutr Exerc Metab 2007;17(5):433–44. 
11.  Goldstein E, Jacobs PL, Whitehurst M, Penhollow T, Antonio J. Caffeine enhances 
upper body strength in resistance-trained women. J Int Soc Sports Nutr 2010;7:18. 
12.  Graham TE, Hibbert E, Sathasivam P. Metabolic and exercise endurance effects of 
coffee and caffeine ingestion. J Appl Physiol 1998;85:883–9. 
13.  Greer F, McLean C, Graham TE. Caffeine, performance, and metabolism during 
repeated Wingate exercise tests. J Appl Physiol 1998;85(4):1502–8. 
14.  Hopkins WG, Marshall SW, Batterham AM, Hanin J. Progressive statistics for 
studies in sports medicine and exercise science. Med Sci Sports Exerc 2009;41(1):3–
13. 
31 
 
 
15.  Hopkins WG. A Spreadsheet for Deriving a Confidence Interval, Mechanistic 
Inference and Clinical Inference from a P Value. Sportscience 2007;11:16–20. 
16.  Hopkins WG. How to Interpret Changes in an Athletic Performance Test. 
Sportscience 2004;8:1–7. 
17.  Ivy JL, Costill DL, Fink WJ, Lower RW. Influence of caffeine and carbohydrate 
feedings on endurance performance. Med Sci Sports 1979;11(1):6–11. 
18.  Ivy JL, Withers RT, Brose G, Maxwell BD, Costill DL. Isokinetic contractile 
properties of the quadriceps with relation to fiber type. Eur J Appl Physiol Occup 
Physiol 1981;47(3):247–55. 
19.  Jacobson BH, Weber MD, Claypool L, Hunt LE. Effect of caffeine on maximal 
strength and power in élite male athletes. Br J Sports Med 1992;26(4):276–80. 
20.  Kline CE, Durstine JL, Davis JM, et al. Circadian variation in swim performance. J 
Appl Physiol 2007;102(2):641–9. 
21.  Kovacs EM, Stegen JHCH, Brouns F. Effect of caffeinated drinks on substrate 
metabolism, caffeine excretion, and performance. J Appl Physiol 1998;85(2):709–
15. 
22.  Lynge, Hellsten. Distribution of adenosine A 1 , A 2A and A 2B receptors in human 
skeletal muscle. Acta Physiol Scand 2000;169(4):283–90. 
23.  Mora-Rodríguez R, Pallarés JG, López-Gullón JM, López-Samanes A, Fernández-
Elías VE, Ortega JF. Improvements on neuromuscular performance with caffeine 
ingestion depend on the time-of-day. J Sci Med Sport 2014; 
24.  Pallarés JG, López-Samanes Á, Moreno J, Fernández-Elías VE, Ortega JF, Mora-
Rodríguez R. Circadian rhythm effects on neuromuscular and sprint swimming 
performance. Biol Rhythm Res 2014;45(1):51–60. 
25.  Pataky MW, Womack CJ, Saunders MJ, et al. Caffeine and 3-km cycling 
performance: Effects of mouth rinsing, genotype, and time of day. Scand J Med Sci 
Sports 2015;n/a – n/a. 
26.  Paton CD, Hopkins WG. Variation in performance of elite cyclists from race to race. 
Eur J Sport Sci 2006;6(1):25–31. 
27.  Porterfield S, Linderman J, Laubach L, Daprano C. Comparison of the Effect of 
Caffeine Ingestion on Time to Exhaustion between Endurance Trained and 
Untrained Men. J Exerc Physiol Online 2013;16(5):90–8. 
28.  Souissi N, Bessot N, Chamari K, Gauthier A, Sesboüé B, Davenne D. Effect of time 
of day on aerobic contribution to the 30-s Wingate test performance. Chronobiol Int 
2007;24(4):739–48. 
29.  Timmins TD, Saunders DH. Effect of caffeine ingestion on maximal voluntary 
contraction strength in upper- and lower-body muscle groups. J Strength Cond Res 
2014;28(11):3239–44. 
32 
 
 
30.  Wakeling JM, Uehli K, Rozitis AI. Muscle fibre recruitment can respond to the 
mechanics of the muscle contraction. J R Soc Interface 2006;3(9):533–44. 
31.  Warren GL, Park ND, Maresca RD, McKibans KI, Millard-Stafford ML. Effect of 
caffeine ingestion on muscular strength and endurance: a meta-analysis. Med Sci 
Sports Exerc 2010;42(7):1375–87. 
32.  Wiles JD, Bird SR, Hopkins J, Riley M. Effect of caffeinated coffee on running 
speed, respiratory factors, blood lactate and perceived exertion during 1500-m 
treadmill running. Br J Sports Med 1992;26(2):116–20. 
33.  Wiles JD, Coleman D, Tegerdine M, Swaine IL. The effects of caffeine ingestion 
on performance time, speed and power during a laboratory-based 1 km cycling time-
trial. J Sports Sci 2006;24(11):1165–71. 
34.  Womack CJ, Saunders MJ, Bechtel MK, et al. The influence of a CYP1A2 
polymorphism on the ergogenic effects of caffeine. J Int Soc Sports Nutr 
2012;9(1):7. 
35.  Woolf K, Bidwell WK, Carlson AG. The effect of caffeine as an ergogenic aid in 
anaerobic exercise. Int J Sport Nutr Exerc Metab 2008;18(4):412–29. 
 
33 
 
 
 Table 1. Descriptive Data 
    Cycling 
 TOT (n = 20) T (n = 7) U (n = 7) 
Height (cm) 175.4 ± 7.4 175.4 ± 6.9 175.9 ± 8.3 
Weight (kg) 73.6 ± 10.9 70.2 ± 10.7 76.0 ± 10.6 
Age (yrs) 24.6 ± 7.7 24.7 ± 8.4 24.3 ± 8.8 
VO2max (ml/kg/min) 57.2 ± 9.3 64.8 ± 7.9 49.2 ± 5.6 
Cycling (hrs/week) 4.9 ± 2.8 7.5 ± 1.8 2.4 ± 0.8 
Resistance (hrs/week) 3.9 ± 6.5 4.9 ± 8.2 3.1 ± 3.3 
Caffeine (mg/week) 648 ± 869 1101 ± 1075 339 ± 529 
  Descriptive data reported as Mean±SD. TOT = Total Subjects, T = Trained, U = Untrained   
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Table 2. 3-km, 30EXT, and 30FLX Data 
 All Subjects Trained Untrained 
Trained vs. 
Untrained 
Variable Treatment PLA CAF CAF vs. PLA AM vs. PM PLA CAF CAF vs. PLA AM vs. PM PLA CAF CAF vs. PLA AM vs. PM CAF vs. PLA 
3-km 
Power 
(W) 
AM 
246.35 
±57.88 
258.05 
±51.97 
7.16±4.38 
(5.64±4.42) 
99/1/0 
Very Likely 
4.23±5.27 
(1.71±5.34) 
85/10/5 
Likely 
272.00 
±61.06 
278.71 
±62.46 
4.48±4.55 
(2.59±3.99) 
91/6/3 
Likely 
7.54±8.04 
(3.54±6.31) 
91/4/4 
Likely 
203.43 
±38.69 
230. 
43 
±39.93 
13.75±22.49 
(13.86±12.08) 
86/3/11 
Likely 
4.99±24.08 
(5.94±13.32) 
62/5/33 
Unclear 
-9.27±22.95 
(-11.27±12.40) 
21/5/75 
Unclear 
PM 
248.25 
±49.80 
258.45 
±53.70 
2.93±3.14 
(3.93±3.20) 
85/13/2 
Likely 
277.71 
±55.01 
277.00 
±66.31 
-3.06±7.31 
(-0.95±5.46) 
16/13/70 
Unclear 
215.71 
±26.02 
234.71 
±41.94 
8.77±11.28 
(7.92±7.62) 
90/4/6 
Likely 
-11.82±12.54 
(-8.86±8.74) 
5/3/93 
Likely 
30 EXT 
AM 
192.65 
±39.05 
194.10 
±47.51 
0.91±4.37 
(-0.25±4.26) 
12/85/3 
Likely (trivial) 
-4.34±5.52 
(-6.19±5.35) 
1/46/53 
Possibly 
214.68 
±28.88 
210.94 
±36.56 
0.29±9.65 
(-2.18±6.61) 
24/56/21 
Unclear 
-6.44±13.65 
(-10.35±8.80) 
10/28/62 
Unclear 
190.55 
±25.07 
199.80 
±32.28 
4.38±7.41 
(4.44±4.00) 
53/43/3 
Possibly 
-0.09±15.49 
(0.09±8.35) 
32/36/32 
Unclear 
-4.09±11.24 
(-6.62±7.29) 
11/39/50 
Unclear 
PM 
190.74 
±38.67 
202.29 
±41.84 
5.24±3.57 
(5.94±3.45) 
72/28/0 
Possibly 
202.92 
±30.89 
219.07 
±25.70 
6.73±11.18 
(8.36±6.85) 
68/27/5 
Possibly 
197.51 
±22.71 
207.56 
±36.44 
4.47±14.39 
(4.36±7.75) 
52/34/14 
Unclear 
2.26±16.84 
(4.00±9.56) 
43/32/26 
Unclear 
30 FLX 
AM 
146.35 
±31.46 
142.36 
±34.98 
-2.69±6.11 
(-3.24±5.67) 
4/62/34 
Possibly 
-0.50±6.81 
(-1.72±6.38) 
12/70/18 
Unclear 
162.39 
±21.56 
159.50 
±23.08 
-1.20±8.54 
(-1.94±4.85) 
13/61/26 
Unclear 
-0.74±11.13 
(-1.26±6.24) 
22/49/29 
Unclear 
143.12 
±22.39 
140.37 
±24.87 
-2.54±21.07 
(-2.20±11.47) 
28/28/44 
Unclear 
-1.86±23.05 
(-0.61±13.19) 
32/26/43 
Unclear 
1.34±22.17 
(0.26±11.92) 
40/27/32 
Unclear 
PM 
145.69 
±31.84 
143.65 
±31.58 
-2.19±3.26 
(-1.52±3.16) 
0/84/16 
Likely (trivial) 
156.55 
±26.69 
155.04 
±21.93 
-0.46±8.50 
(-0.68±4.70) 
16/63/21 
Unclear 
147.08 
±18.66 
146.45 
±29.03 
-0.67±12.36 
(-1.59±8.27) 
23/47/30 
Unclear 
0.21±13.99 
(0.90±8.98) 
30/41/29 
Unclear 
Values for Placebo (PLA) and Caffeine (CAF) reported as Mean±SD. Comparison values reported as adjusted (actual in parenthesis) Mean±90% CI 
for differences between change scores (i.e. AM vs. PM), % likelihoods of positive effect/trivial effect/negative effect and semantic inferences. 
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Table 3. 120EXT, 120FLX, 240EXT, and 240FLX Data 
 All Subjects Trained Untrained 
Trained vs. 
Untrained 
Variable Treatment PLA CAF CAF vs. PLA AM vs. PM PLA CAF CAF vs. PLA AM vs. PM PLA CAF CAF vs. PLA AM vs. PM CAF vs. PLA 
120 EXT 
AM 
171.34 
±31.67 
171.27 
±32.99 
-0.25 ±3.54 
(-0.13±3.29) 
4/91/6 
Likely (trivial) 
-1.57±4.56 
(-2.00±4.29) 
3/75/22 
Likely (trivial) 
185.27 
±31.06 
186.52 
±30.33 
1.07±6.20 
(0.78±3.46) 
22/69/9 
Unclear 
0.67±7.12 
(-0.38±4.13) 
23/62/15 
Unclear 
171.11 
±22.71 
173.60 
±27.64 
1.44±10.77 
(1.11±6.05) 
35/46/19 
Unclear 
-1.38±14.28 
(-1.69±7.85) 
27/34/39 
Unclear 
-0.36±11.73 
(-0.33±6.57) 
27/42/31 
Unclear 
PM 
171.70 
±29.52 
174.73 
±29.18 
1.32 ±3.05 
(1.86±2.92) 
10/90/1 
Likely (trivial) 
183.49 
±25.88 
185.03 
±20.30 
0.41±4.57 
(1.16±2.84) 
11/83/7 
Unclear 
173.22 
±23.26 
178.78 
±29.81 
2.81±11.08 
(2.80±5.96) 
44/42/14 
Unclear 
-2.40±11.69 
(-1.65±6.32) 
18/40/42 
Unclear 
120 FLX 
AM 
147.00 
±31.40 
141.90 
±32.35 
-4.58±5.24 
(-3.74±5.00) 
1/43/56 
Possibly 
-3.28±5.94 
(-2.69±5.65) 
2/59/39 
Possibly 
(trivial) 
157.31 
±22.08 
156.72 
±18.80 
-1.45±4.77 
(-0.18±4.57) 
3/81/15 
Likely (trivial) 
-0.40±5.82 
(0.98±5.29) 
9/78/13 
Unclear 
147.43 
±30.92 
137.59 
±25.61 
-6.09±23.11 
(-6.37±12.42) 
21/22/57 
Unclear 
-3.50±24.98 
(-3.84±13.43) 
29/23/48 
Unclear 
4.64±23.60 
(6.20±12.92) 
51/24/25 
Unclear 
PM 
147.61 
±32.51 
146.04 
±32.43 
-1.30±3.04 
(-1.04±2.84) 
0/94/6 
Likely (trivial) 
156.16 
±23.62 
154.26 
±22.28 
-1.04±4.11 
(-1.16±3.44) 
3/88/9 
Likely (trivial) 
153.99 
±28.46 
150.89 
±32.96 
-2.59±12.92 
(-2.54±6.95) 
17/42/41 
Unclear 
1.54±13.22 
(1.38±7.42) 
35/43/22 
Unclear 
240 EXT 
AM 
154.59 
±28.61 
158.43 
±33.59 
2.02±3.14 
(1.95±2.91) 
18/81/0 
Likely (trivial) 
1.27±4.62 
(0.15±4.50) 
19/77/4 
Likely (trivial) 
161.08 
±22.62 
165.26 
±28.98 
3.81±9.81 
(2.21±5.97) 
51/40/9 
Unclear 
4.45±11.41 
(1.82±6.92) 
55/34/11 
Unclear 
156.57 
±33.40 
158.44 
±35.18 
1.26±9.76 
(0.88±5.63) 
32/50/18 
Unclear 
-4.07±15.12 
(-3.65±9.32) 
19/30/52 
Unclear 
2.54±12.79 
(1.32±7.58) 
44/36/20 
Unclear 
PM 
157.85 
±29.86 
159.99 
±26.08 
0.75±3.55 
(1.80±3.58) 
9/89/2 
Likely (trivial) 
166.08 
±30.33 
166.23 
±27.07 
-0.64±7.49 
(0.39±4.53) 
15/62/23 
Unclear 
158.73 
±30.29 
164.80 
±23.26 
5.33±13.12 
(4.54±8.25) 
59/30/11 
Unclear 
-5.97±14.25 
(-4.15±8.88) 
12/27/61 
Unclear 
240 FLX 
AM 
143.41 
±33.58 
140.54 
±36.89 
-2.77±6.69 
(-2.69±6.20) 
4/63/33 
Possibly 
-2.14±7.57 
(-2.94±7.11) 
7/65/29 
Unclear 
152.35 
±12.96 
151.95 
±16.11 
-1.29±5.99 
(-0.41±3.65) 
5/78/16 
Unclear 
1.45±8.12 
(1.31±5.00) 
24/65/10 
Unclear 
145.04 
±37.96 
141.52 
±36.68 
-2.60±26.82 
(-2.48±14.35) 
31/25/45 
Unclear 
-3.07±28.02 
(-2.49±15.19) 
31/23/46 
Unclear 
1.31±27.48 
(2.07±14.81) 
41/25/34 
Unclear 
PM 
143.95 
±33.31 
144.51 
±34.20 
-0.64±3.85 
(0.25±3.77) 
2/94/5 
Likely (trivial) 
154.69 
±19.86 
152.11 
±20.63 
-2.74±6.43 
(-1.71±3.99) 
4/66/30 
Possibly 
148.92 
±33.65 
149.97 
±37.10 
0.47±11.75 
(0.01±6.78) 
26/53/21 
Unclear 
-3.21±12.63 
(-1.72±7.42) 
14/44/42 
Unclear 
Values for Placebo (PLA) and Caffeine (CAF) reported as Mean±SD. Comparison values reported as adjusted (actual in parenthesis) Mean±90% CI 
for differences between change scores (i.e. AM vs. PM), % likelihoods of positive effect/trivial effect/negative effect and semantic inferences.  
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Figure 1. 3-km Time Trial Performance 
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Figure 2. Percent Change 3-km Time 
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FIGURE LEGENDS 
Figure 1.  
Effects of Caffeine during 3-km Time Trial performance in seconds: Bars depict mean 
time in seconds (± SE). (a) Signifies a ‘very likely’ improvement between placebo and 
caffeine. (b) Signifies a ‘likely’ improvement between placebo and caffeine. (c) Signifies 
a ‘likely’ increased benefit in the AM over PM. (d) Signifies a ‘likely’ increased benefit 
in the untrained over trained. 
 
Figure 2.  
Effects of Caffeine during 3-km Time Trial performance in seconds: Markers indicate 
mean percent change from placebo and bars depict ± 90% confidence interval. Dashed 
lines signify threshold value of a meaningful effect (0.3 × CV). (a) Signifies a ‘very 
likely’ improvement between placebo and caffeine. (b) Signifies a ‘likely’ improvement 
between placebo and caffeine. (c) Signifies a ‘likely’ increased benefit in the AM over 
PM. (d) Signifies a ‘likely’ increased benefit in the untrained over trained. 
 
 
 
 
 
 
 
 
 
 
 
39 
 
Appendix I 
Appendices 
James Madison University 
Department of Kinesiology 
Consent for Investigative Procedure 
 
I, ______________________, hereby agree on _____________ (date) to participate in the 
research project conducted by Christopher J. Womack, Ph.D., Nicholas D. Luden, Ph.D., 
James Boyett, and Gabe Giersch from James Madison University titled The Effect of 
Genetics, Training Status, and Time-of-day Consumption on the Ergogenic Properties of 
Caffeine. 
 
The purpose of this study is to determine whether or not genetics influences the effects of 
caffeine supplementation on performance. Additionally, this study aims to determine 
whether trained individuals benefit more from caffeine supplementation than untrained 
during cycling and muscular strength performance. The final purpose of this study is to 
determine whether the time of day affects whether caffeine is beneficial for cycling 
performance.  
 
 
Subject Responsibility 
 
I understand that I will undergo the following testing in the study: 
 
This study consists of seven separate exercise tests performed on both on a muscle strength 
device and a stationary bike (cardiovascular fitness test, two familiarization tests, and four 
3km time trial tests). All testing will occur in Godwin Hall, room 209, on the campus of 
James Madison University. You will also be asked about lifestyle behaviors such as 
smoking and physical activity and complete dietary and physical activity records. The total 
time commitment is estimated to be less than 10 hours over the course of 4-6 weeks. 
 
Pre-testing 1 (60 min):  
 
After completing this consent form and the health history screening, if you meet the 
inclusion criteria for the study, researchers will measure your height and body weight. 
 
You will then be asked to perform a maximal cardiovascular fitness test to determine your 
peak oxygen consumption (VO2max). You will be asked to ride a stationary bike at an initial 
workload that is ‘fairly easy’. The workload will then be increased every two minutes until 
exhaustion is reached, determined by either: 1) your request to stop due to fatigue, or 2) 
inability to maintain a cadence of ≥50 revolutions per minute. You will be verbally 
encouraged to continue to obtain an accurate measurement of VO2max. To access oxygen 
consumption, you will need to breathe through a mouthpiece/breathing apparatus which 
collects expired air throughout the test (10-15 minutes). 
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Familiarization Trials (n =2; 30 minutes each):  
 
On two occasions, you will be asked to perform peak skeletal muscle function testing and 
a 3-km cycling practice trial on a stationary bike. You will warm-up with a 5 minute 
treadmill test at 3.5 mph, followed by a strength test. This will consist of two warm-up 
repetitions followed by two maximal exertion isokinetic peak torque measurements at 30, 
120, and 240 degrees/sec. One set consists of two sub-maximal repetitions immediately 
followed by two maximal repetitions, with sixty seconds of rest between two sets at the 
same velocity. Once all exertions are completed at a given velocity, 60 seconds of rest will 
be given before proceeding to the next velocity. After strength testing is complete, you will 
move to a stationary bicycle to complete the 3-km time trial. You will be encouraged to 
treat the time trial like a competition. 
 
Experimental Trials (n=4; 120 minutes each): 
 
You will report to the laboratory 60 minutes prior to exercise testing. You will rest in a 
seated position for 5 minutes, after which a blood sample will be obtained for measurement 
of caffeine/caffeine metabolite levels (one of the samples will also be used to extract DNA 
for genotyping). Immediately following the blood draw, you will ingest either placebo or 
caffeine capsules, after which you will wait for ~60 minutes in the laboratory until exercise 
testing. Immediately prior to exercise testing, a second blood sample will be obtained for 
the measurement of caffeine/caffeine metabolite levels. Following the blood draw, you will 
complete the peak muscle function test and 3-km time trial described above.  
 
Supplementation Protocol: 
No supplementation will be given during the familiarization trials. You will be randomly 
assigned a treatment order. Treatments will be: 1. Placebo capsule containing flour 
administered 1hr prior to exercise at 8:00am 2. Caffeine capsule containing 6 mg/kg 
bodyweight caffeine administered 1hr prior to exercise at 8:00am 3. Placebo capsule 
containing flour administered 1hr prior to exercise at 6:00pm 4. Caffeine capsule 
containing 6 mg/kg bodyweight caffeine administered 1hr prior to exercise at 6:00pm. 
 
Dietary and Exercise Controls: 
You will be asked to record food intake 24 hours prior to the first familiarization trial. You 
will then be given a copy of the dietary log and asked to replicate food intake for 24 hours 
prior for each subsequent trial. Additionally, you will be asked to abstain from alcohol and 
caffeine consumption for 24 hours prior to testing in all trials. Additionally, you will be 
asked to arrive at the laboratory in a fasted state (no food intake within the past 4 hours). 
Finally, you will be asked to refrain from heavy exercise for 48 hours prior to testing, as 
well as record any physical activity during the 48 hours prior to testing. You will be asked 
to maintain consistent physical activity habits before all trials. 
 
DNA Sampling: 
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We will extract a sample of your DNA from one of your blood samples. DNA and blood 
samples will be stored in our laboratory freezer for at least 3 years to allow us to conduct 
follow-up studies in the event that new discoveries are made related to DNA and caffeine 
metabolism. Your sample will be coded so that nobody except the primary investigators 
can identify which sample is yours. The DNA testing will involve determining sequences 
of DNA for specific genes that are related to caffeine metabolism. We will not use this 
DNA for any other purpose.  The results of this genetic testing will only be available to the 
primary investigator and you. These results will not be made public and will be stored in a 
locked file cabinet. 
 
 
Risks/Benefits: 
 
Skeletal Muscle Function 
 
The risks of muscle function testing include soreness from exertion 24-48 hours post and 
potential lightheadedness or loss of consciousness if correct form is not utilized.  You will 
be instructed in correct form and breathing techniques prior to testing. 
 
Cardiovascular Exercise (3-km Time Trial and VO2max test) 
 
According to the American College of Sports Medicine’s Guidelines for Exercise Testing 
and Prescription, the risk associated with heavy exercise for individuals categorized as 
“low risk” is very minimal, and physician supervision is not necessary.  The conditions that 
the exercise sessions are to take place are likely safer than the typical exercise environments 
of the subjects. If you do not meet ACSM criteria for “low risk”, you will not be allowed 
to participate in the study. In the unlikely event of cardiac or other complications during 
exercise, an emergency plan is in place. This includes immediate access to a phone to call 
emergency personnel. In addition, at least one of the listed investigators will be present 
during the exercise sessions, and all are CPR certified.   
 
Blood Sampling 
 
The risks of blood sampling using venipuncture include possible mild bruising, and the risk 
of transfer of blood-borne pathogens, as well as possible risks of infection or skin irritation.  
These risks are considered to be minimal, and all safety precautions for handing blood 
samples will be followed according to OSHA protocols, including: investigators will wear 
latex gloves at all times during blood sampling and testing. A sharps container lined with 
a biohazard bag will be used for all sharp objects involved in the blood sampling; all other 
materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in a separate 
waste disposal unit lined with a biohazard bag. All investigators who will be involved in 
blood draws (and handling of blood) have been trained in these phlebotomy techniques, 
and completed JMU blood-borne pathogen training. The total amount of blood obtained 
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during this study is approximately 24 ml. For reference, this amount is ~ 6% of a can of 
soda, or 5% of the amount given when donating blood in a single session (approximately 
1 pint, or 473 ml).  
 
Caffeine Ingestion 
 
The risks and side effects associated with caffeine supplementation include: rapid heart 
rate, elevated blood pressure, headache, nausea, vomiting, restlessness, agitation, and 
anxiety. 
 
Performance incentive: 
 
The top 5 trained performers (fastest finishing placebo time, use of caffeine would 
necessitate an unfair advantage to possible genetic responders) will be entered into a 
drawing to win $150. Trained individuals in the top 6-10 placebo time will be entered into 
a drawing to win $75. An identical incentive method will be used for the untrained subjects 
(1 $150 and 1 $75). 
 
 
Confidentiality  
The results of this research will be presented at conferences and published in exercise 
science journals.  The results of this project will be coded in such a way that your identity 
will not be attached to the final form of this study.  The researcher retains the right to use 
and publish non-identifiable data.  However, you can ask that your data be removed from 
the study at any point prior to presentation and publication.  While individual responses 
are confidential, aggregate data will be presented representing averages or generalizations 
about the responses as a whole.  All data will be stored in a secure location accessible only 
to the researcher.  Final aggregate results will be made available to you upon request. 
 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  Should 
you choose to participate, you can withdraw at any time without consequences of any kind.  
Your right to withdraw includes the right to request that your DNA and blood samples be 
discarded at any time.  You should be aware that the DNA sample is subject to court 
subpoena. To dispose of your samples, your samples will be rinsed down a chemical drain 
in our laboratory or will be disposed of in a biohazard container. Again, your sample will 
not be identifiable without the coding document that will be locked away in a filing cabinet.  
 
Questions 
You may have questions or concerns during the time of your participation in this study, or 
after its completion.  If you have any questions about the study, contact Nicholas D. Luden, 
Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068 
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Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I certify 
that I am at least 18 years of age. 
   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   
  Date    Date 
 
For questions about your rights as a research subject, you may contact the chair of JMU’s 
Institutional Review Board (IRB).  Dr. David Cockley, (540) 568-2834, cocklede@jmu.edu
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AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 
   You take prescription medication(s) 
 
 
 
Cardiovascular risk factors 
   You are a man older than 45 years 
   You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
   You are physically inactive (i.e. you get < 30 minutes of  
   physical activity on at least 3 days of the week) 
   You are > 20 pounds overweight 
 
 
   None of the above
If you marked any of these statements 
in this section, consult your physician 
or other appropriate health care 
provider before engaging in exercise.  
You may need to use a facility with a 
medically qualified staff. 
If you marked two or more of the 
statements in this section, you should 
consult your physician or other 
appropriate health care provider 
before engaging in exercise.  You 
might benefit from using a facility 
with a professionally qualified 
exercise staff to guide your exercise 
program. 
You should be able to exercise safely 
without consulting your physician or 
other appropriate health care provider 
in a self-guided program or almost any 
facility that meets your exercise 
program needs. 
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Subject Prescreening Information & Caffeine Habits 
 
 
Age: years 
 
Height       Weight      
  
 
 
Typical Exercise Habits over the Past 3-6 Months: 
 
Average number of days of cycling per week     
 
Average number of hours of cycling per week    
 
Briefly describe your cycling habits over the past 3-6 months: 
 
 
 
 
Average number of days of resistance exercise/weight lifting per week ___________ 
 
Average number of hours of resistance exercise/weight lifting per week __________ 
 
Briefly describe your resistance training habits over the past 3-6 months: 
 
 
 
 
Do you have a muscle or joint injury/condition that precludes the completion of the 
cycling or muscle function protocol? If yes, please explain. 
 
 
Are you allergic to wheat? 
 
Do you have gluten intolerance? 
 
Are you allergic to latex? 
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Caffeine Habits: 
 
 
Please list your approximate WEEKLY intake of the following: 
 
Cups of coffee: 
Cups of tea: 
 
Cans (12 oz) of caffeinated soda: 
 
Servings of chocolate: 
 
Doses of caffeinated pills (No-Doz, Vivarin, etc.): 
 
Other caffeinated beverages not listed (please list specific drink and weekly intake):  
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Physical Activity Records 
 
Subject #    Trial #    Date:   
 
Date 
Type of Exercise 
Performed 
Duration of 
Exercise (minutes) 
Intensity of 
Exercise 
(use scale below) 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
 
Intensity Scale 
 
6 
7 Very, very light 
8 
9 Very light 
10 
11 Fairly light 
12 
13 Somewhat hard 
14 
15 Hard 
16 
17 Very hard 
18 
19 Very, very hard 
20
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TRAIT Study 
Subject Information 
Subject #: _________   
Demographic Information 
Height:_______ 
Weight:_______ 
 
BIODEX 
Chair position:_______ 
Seatback position:_______ 
Machine position:_______ 
Seat height:________ 
Arm attachment position:_______ 
 
VELOTRON 
Seat height: _______       
Seat fore/aft: _______      
Handlebar height: _______      
Handlebar fore/aft: _______  
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TRAIT Study 
VO2 Peak Test 
Velotron Settings:       Demographic 
Information 
 Seat height: _______      Height:________ 
 Seat fore/aft: _______     Weight:________ 
 Handlebar height: _______     Age:_______ 
 Handlebar fore/aft: _______     RHR:_______ 
VO2 Peak Test: 
 Starting workload: _______ (watts) 
 Increase workload 25 watts every minute. Proceed with 1-minute stages until 
subject requests to stop due to fatigue or when subject is no longer able to 
maintain >50rpm for 10 seconds 
Stage  Time   Watts   HR   RPE 
1  ______  ______  ______           ______ 
2  ______  ______  ______           ______ 
3  ______  ______  ______           ______ 
4  ______  ______  ______           ______  
5  ______  ______  ______           ______ 
6  ______  ______  ______           ______ 
7  ______  ______  ______           ______ 
8  ______  ______  ______           ______ 
9  ______  ______  ______           ______ 
10  ______  ______  ______           ______ 
11  ______  ______  ______           ______ 
12  ______  ______  ______           ______ 
13  ______  ______  ______           ______  
14  ______  ______  ______           ______ 
15  ______  ______  ______           ______ 
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TRAIT Study 
Experimental Trial 
Subject #: _________           Date:____________        Time:________AM/PM        
        Purple/Gold 
Trial:     FAM1 FAM2  1  2  3  4 
Explain the protocol in detail to ensure that the subject knows what is expected. 
Verify that the subject is fasted (4hr food/drink, 12hr caffeine) 
 Subject sits in standard position for 5 minutes 
 Pre-treatment blood draw (time:________am/pm)  * Let clot for 30 minutes 
 Treatment given (time:__________am/pm) 
 Subject remains in laboratory for 60 minutes 
 Post-treatment blood draw (time:_________am/pm) 
 
5 minute warm up on treadmill (3.5mph) 
 
Biodex 
Speed   Flexion PeakT  Extension PeakT 
30   ________   ________ 
30   ________   ________ 
120   ________   ________ 
120   ________   ________ 
240   ________   ________ 
240   ________   ________ 
 
Velotron 
Time trial time:________ Avg Watts:________ 
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Subject: ______________ 
 
Date: ______________ 
 
 
      Trial 1       Trial 2       Trial 3       Trial 4 
Capsule   PLA    CAF    PLA   CAF    PLA   CAF    PLA   CAF 
 
Confidence ___________  ___________  ___________  ___________ 
 
 
 
 
**Confidence rated on a scale from 1-10. 10 being 100% confidence and 1 being not 
confident at all 
 
 
 
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
 
 
 
Subject #: ___________ 
 
Preferred Contact: ____________________________________ 
 
Do you want an End-Of-Study Packet?      Y / N ?
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